WCCT Global Conducts 28 Successful Hepatitis C Clinical Studies

COSTA MESA, Calif., March 6, 2013/PRWeb/–WCCT Global, full service contract research organization, announces today that the organization has conducted 28 Hepatitis C clinical studies. These studies span all phases of research including First in Human studies through late phase Hepatitis C clinical studies. Hepatitis C effects populations all over the world. Being that Hepatitis C is responsible for 75% of all liver disease in the world, WCCT Global has made a commitment to focusing extensive energy on increasing their expertise and experience in this therapeutic area.

Unlike most contract research organizations, WCCT Global has vast experience in multiple therapeutic areas. Most CROs merely have a general therapeutic knowledge, and are therefore unable to provide a therapeutic-specific solution for conducting clinical research. Thus, WCCT is able to offer sponsors unique clinical project management services for all phases of clinical research, in nearly any patient population.

WCCT Global has a very large database of Hepatitis C patients that they are able to reach out to in order to quickly enroll in Hepatitis C clinical studies. WCCT Global’s VP of Business Development Talia Nikolao states, “we feel privileged to be working on treatments for the Hepatitis C virus that affects nearly 170 million people globally. We want to further progress the treatments for this terrible virus that is affecting such a large part of our global population.” WCCT Global is looking to continue to expand this early phase clinical study work with many more upcoming studies in HCV.